We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Failure to Warn Advisory Board Is Evidence of Review Flaws
Failure to Warn Advisory Board Is Evidence of Review Flaws
May 5, 2006
The FDA’s failure to warn its advisory committee of substantial known problems with a company’s drug review is evidence of larger flaws in the agency’s drug review processes, Sen. Chuck Grassley (R-Iowa) argues.